CUE
Cue Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.53
−3.46%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$38.91
From 52W high−3.46%
Volume259665.00
Market cap$265.37M
P/E (TTM)—
P/S (TTM)7.0x
Div yield—
Key dataSep 18, 2026
Open
$38.91
From 52W high
−3.46%
Volume
259665.00
Market cap
$265.37M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
P/E (TTM)
—
RSI (14)
69.2
MomentumView details →
1D Return
−3.46%
YTD Return
+321.93%
SummaryUpdated Jun 1, 2026
Cue Biopharma, Inc. (NASDAQ:CUE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as Imagen Biopharma, Inc., the company changed its name to Cue Biopharma in October 2016 and went public in January 2018. The company focuses on developing innovative biologic drugs that selectively modulate the human immune system to treat cancers, chronic infectious diseases, and autoimmune disorders through its proprietary Immuno-STAT platform technology.
Similar companies
Latest newsMore news →
Cue Biopharma reported positive topline results from a clinical trial of CUE-221.5h agoCue Biopharma announced the appointment of James M. Ahlers as Chief Financial Officer on August 3, 2026.48d agoCue Biopharma appointed Sumita Ray as Chief Legal & Compliance Officer and Corporate Secretary.111d ago